ClinicalTrials.gg

Program

lorundrostat hydrobromide

Also written as “MLS101 psilocybin”, “MLS-101 (Part I)” and “MLS-101 (Part II)”.

Its studies are mostly in Premenstrual Dysphoric Disorder, led by 3 companies.

Furthest: phase 2, since Jul 20, 20213 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mineralys Therapeutics10 open or runningphase 2since Jul 20, 2021Jul 20, 2021none ahead
MycoMedica Life Sciences PBC11 open or runningphase 1since Aug 25, 2026Aug 25, 2026Sep 2027phase 1 · NCT07818720
Tanabe Pharma10 open or runningphase 1since Oct 31, 2016Oct 31, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2016First study: phase 1 study in HealthyNew to Tanabe PharmaTanabe Pharma · NCT02953132 · 116 enrolled · Netherlands
  2. Jul 20, 2021Mineralys Therapeutics's first study: phase 2 study in Hypertension, RenalNew to Mineralys TherapeuticsMineralys Therapeutics · NCT05001945 · 200 enrolled · United States
  3. Aug 25, 2026MycoMedica Life Sciences PBC's first study: phase 1 study in Premenstrual Dysphoric DisorderNew to MycoMedica Life Sciences PBCMycoMedica Life Sciences PBC · NCT07818720 · 32 planned

Ahead

  1. Sep 2027Primary completion: phase 1 study in Premenstrual Dysphoric DisorderMycoMedica Life Sciences PBC · NCT07818720

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07818720Premenstrual Dysphoric Disorder1Not yet recruitingMycoMedica Life Sciences PBCSep 202732
NCT05001945Hypertension, Renal · United States2CompletedMineralys TherapeuticsSep 7, 2022200
NCT02953132Healthy · Netherlands1CompletedTanabe PharmaMay 2017116

How it is read

Names in the registry

  • “MLS101 psilocybin”, 1 entry
  • “MLS-101 (Part I)”, 1 entry
  • “MLS-101 (Part II)”, 1 entry
  • “MT-4129”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.